The global insomnia market is highly fragmented, along with entry barriers for new players in terms of
product efficacy, innovation, and cost. However, insomnia therapeutics center on commonly available
low-dose sedating antidepressants and Nonbenzodiazepines, despite introduction of several novel
agents, mainly because of low awareness among patients.
Insomnia Market Covers the Table of Contents With Segments, Key Players And Region. Based on
therapy type, Insomnia Market is sub segmented into non-pharmacological and pharmacological
therapy. Non-pharmacological therapy is further categorized into hypnotherapy, cognitive behavioral
therapy, medical devices, and other non-pharmacological therapy. Pharmacological therapy is further
divided into prescription sleep aids and over-the-counter sleep aids.
North America accounted for the maximum contribution to the total revenue generated, owing to the
high prevalence rate of insomnia, presence of high disposable income, and high demand for over-the-
counter (OTC) drugs.
Major Players profiled in the Insomnia market report incorporate: Merck & Co. Inc., Sanofi, Pfizer, Inc.,
Takeda Pharmaceutical Company Ltd., Purdue Pharmaceuticals L.P., Eisai, Co. Ltd.
Latest Industry News
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that
BELSOMRA (suvorexant) is now available at pharmacies in the United States for the treatment of
insomnia in adults who have difficulty falling asleep and/or staying asleep. BELSOMRA is the only orexin
receptor antagonist approved for the treatment of insomnia in the United States. Orexin is one of the
many neurotransmitters in the brain involved in promoting wakefulness, and BELSOMRA selectively
blocks orexin receptors. In doing this, BELSOMRA is thought to suppress wake drive in the brain.
“Insomnia is a serious condition that affects millions of Americans,” said David Cloud, CEO of the
National Sleep Foundation. “With BELSOMRA, healthcare professionals and patients now have an
additional option to consider.”
The recommended dose of BELSOMRA is 10 mg, taken no more than once per night and within 30
minutes of going to bed, with at least 7 hours remaining before the planned time of awakening. The
total dose should not exceed 20 mg once daily.
Request a Discount on standard prices of this premium report @
https://www.businessindustryreports.com/check-discount/162966 .
Region segment: This report is segmented into several key regions, with sales, revenue, market share
(%) and growth Rate (%) of Insomnia in these regions, from 2014 to 2023 (forecast), covering: North
America, Europe, Asia Pacific, Middle East & Africa and South America.
Significant points in table of contents: Market Definition, Market Overview, Business Introduction,
Segmentation (Region Level), Segmentation (Type Level), Segmentation (Industry Level), Segmentation